This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Moody's Foresees Junky Valeant Pharmaceuticals Deals

NEW YORK (TheStreet) -- Bond ratings firm Moody's isn't sold on the idea that the four largest generic drug manufacturers Teva Pharmaceuticals (TEVA), Mylan (MYL), Actavis (ACT - Get Report) and Sandoz can continue to consolidate after years of merger activity in the sector. Moody's also would likely rate a takeover of any of the generics "big four" by serial acquirer Valeant Pharmaceuticals (VRX - Get Report) as junk.

Will Valeant Overdose on Acquisitions?

Bausch + Lomb Success Less than Meets the Eye

"Mergers between any of the top four generic players would face significant challenges. The high level of fragmentation in the generic pharmaceutical industry and consolidation among its large customers argue for M&A among generic pharmaceutical players. But consolidation between the top four players --Teva Pharmaceutical, Mylan, Actavis plc, and Sandoz (owned by Novartis AG) -- is unlikely given antitrust challenges that would likely require significant divestitures," Moody's lead analyst Jessica Gladstone wrote in a Wednesday note.

The firm does see the prospect that Valeant Pharmaceuticals would go after one of the big four in the generics space, however, it said such a deal would likely be rated below investment grade.

"A hypothetical merger between Valeant and one of the top four generic players could be rated below investment grade. Given Valeant Pharmaceuticals' M&A appetite, we cannot completely rule out that it would buy a generic player," Moody's said.

A merger of a generic drug maker would be outside of Valeant's normal interest in specialty drug makers, Moody's noted. However, the company has recently indicated to the media and in investor presentations that it is bracing for a next big acquisition after buying Medicis and Bausch + Lomb in recent years.

Combining Valeant's existing businesses with a large generic drug manufacturer would give the company size, scale and diversification, however, it would also indicate continued aggressive financial policies that would preclude an investment grade rating, Moody's said.

After making a handful of acquisitions, Valeant Pharmaceuticals promised to pay down its debt and deleverage. Instead, the company has continued to make acquisitions, dramatically increasing its debt stock.

Valeant's long-term debt stood at over $17 billion as of year-end 2013, up nearly three-fold from 2011 year-end levels and nearly five-fold from 2010 levels.

Still, Valeant's acquisitive ways have paid off for shareholders, including ValueAct Capital, which currently holds seats on the company's board of directors.

Valeant shares have risen over 1000% over the past five years, excluding dividends, as the company has divested poorly performing assets and used cheap financing markets to grow by acquisition.

Valeant was trading less than 1% lower in Wednesday trading at $130.66.

-- Written by Antoine Gara in New York

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ACT $296.43 -0.40%
VRX $197.39 -0.62%
YHOO $44.13 -0.69%
AAPL $124.25 -0.14%
FB $81.66 -0.67%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs